Please choose your delivery country and your customer group
This is the second annual report on the grant 'Proto-oncogene PML and tumor evasion in prostate cancer'. The purpose of the grant proposal is to identify the molecular mechanisms of tumor evasion of host anti-tumor immunity. We proposed to identify the antigen presentation defects in human prostate cancer samples and to use mouse prostate cancer model (TRAMP mice) to study the immune regulation and immune tolerance in prostate cancer. In the past funding period, we have shown that thymic clonal deletion is a major mechanism for immune tolerance to tumor antigens that previously regarded as prostate specific. We provided the direct evidence that the T cell repertoire specific for tumor antigens can be shaped by negative selection in the thymus. During the process of examine antigen presentation defects in different tumor cell lines, we identified a new novel mechanism for antigen presentation gene regulation, i. e. the degradation of mRNA of an antigen presentation gene was involved in tumor evasion of immune recognition. We have also analyzed the transcription regulation of one of the antigen presentation genes and identified two new promoter regions and the essential role of the interferon response factor- binding element (IRFE) in that promoter region.